$43.73
-0.18-0.41%
Últ. Act.: Oct 23, 9:30 AM
Ionis Pharmaceuticals (IONS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Ionis Pharmaceuticals (IONS) publicó su última previsión de julio 29, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $875M - $900M para el período.
En comparación con la previsión anterior, Ionis Pharmaceuticals mantenido redujo su previsión de ingresos desde un rango anterior de $875M - $900M.
Ionis Pharmaceuticals ha emitido 7 actualizaciones de orientación entre el abril 30, 2025 y el julio 29, 2026. During this period, the company raised its outlook 3 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.95 | $-0.80 | $-1.26 | $-1.12 |
| Actual | $-0.42 | $-0.30 | $-1.15 | $-0.61 |
| Surprise | +55.8% | +62.5% | +8.73% | +45.3% |
| Revenue | ||||
| Estimate | $189.6M | $194.9M | $155.9M | $130.3M |
| Actual | $268.0M | $246.0M | $203.0M | $157.0M |
| Surprise | +41.3% | +26.2% | +30.2% | +20.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.97 | $-0.92 | $-0.91 | $-0.72 |
| Revenue | ||||
| Consensus | $184.5M | $235.2M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $-0.42 | $-0.95 | 55.8 % |
| Q1 | Apr 29, 2026 | $-0.30 | $-0.80 | 62.5 % |
| Q4 | Feb 25, 2026 | $-1.15 | $-1.26 | 8.73 % |
| Q3 | Oct 29, 2025 | $-0.61 | $-1.12 | 45.3 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $268.00M | $189.62M | 41.3 % |
| Q1 | Apr 29, 2026 | $246.00M | $194.89M | 26.2 % |
| Q4 | Feb 25, 2026 | $203.00M | $155.91M | 30.2 % |
| Q3 | Oct 29, 2025 | $157.00M | $130.27M | 20.5 % |